These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28496443)

  • 1. Higher Levels of Secretory IgA Are Associated with Low Disease Activity Index in Patients with Reactive Arthritis and Undifferentiated Spondyloarthritis.
    Salas-Cuestas F; Bautista-Molano W; Bello-Gualtero JM; Arias I; Castillo DM; Chila-Moreno L; Valle-Oñate R; Herrera D; Romero-Sánchez C
    Front Immunol; 2017; 8():476. PubMed ID: 28496443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Discriminative Values of the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Spondyloarthritis-Related Axial Arthritis.
    Tsang HHL; Chung HY
    J Clin Rheumatol; 2017 Aug; 23(5):267-272. PubMed ID: 28661926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme.
    Fernández-Espartero C; de Miguel E; Loza E; Tomero E; Gobbo M; Descalzo MA; Collantes-Estévez E; Mulero J; Muñoz-Fernández S; Zarco P; Carmona L;
    Ann Rheum Dis; 2014 Jul; 73(7):1350-5. PubMed ID: 23709245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing of SIgA serum levels may reflect subclinical intestinal involvement in non-radiographic axial and peripheral spondyloarthritis.
    Arias I; Herrera D; Bautista-Molano W; Bello-Gualtero JM; De Avila J; Salas-Cuestas F; Romero-Sánchez C
    Clin Rheumatol; 2021 Apr; 40(4):1343-1351. PubMed ID: 32876782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
    Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis.
    Castrejón I; Pincus T; Wendling D; Dougados M
    RMD Open; 2016; 2(2):e000235. PubMed ID: 27486525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
    Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
    Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mannose-Binding Lectin Deficiency in Brazilian Patients with Spondyloarthritis.
    Skare TL; Nisihara R; Cieslinski JZ; Zeni JO; Rasera HN; Messias-Reason I; Utiyama SR
    Immunol Invest; 2017 Feb; 46(2):183-189. PubMed ID: 27911110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS).
    Solmaz D; Yildirim T; Avci O; Tomas N; Akar S
    Clin Rheumatol; 2016 Jul; 35(7):1753-8. PubMed ID: 26670454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
    Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
    Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibromyalgia in Spondyloarthritis: Effect on Disease Activity Assessment in Clinical Practice.
    Wach J; Letroublon MC; Coury F; Tebib JG
    J Rheumatol; 2016 Nov; 43(11):2056-2063. PubMed ID: 27633820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory features of patients with undifferentiated spondyloarthritis and ankylosing spondylitis.
    Gemcioglu E; Erten S
    Rev Med Chil; 2021 Oct; 149(10):1423-1429. PubMed ID: 35319631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of pentraxin 3 in patients with spondyloarthritis.
    Nisihara R; Skare TL; Zeni JO; Rasera H; Lidani K; Messias-Reason I
    Biomarkers; 2018 Feb; 23(1):14-17. PubMed ID: 28043168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Scoring of disease activity using BASDAI and ASDAS method in ankylosing spondylitis].
    Bobek D; Zagar I; Kovač-Durmiš K; Perić P; Ćurković B; Babić-Naglić Ð
    Reumatizam; 2012; 59(1):5-10. PubMed ID: 25486721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment.
    Patil A; Upadhyaya S; Dawar R; Dadhaniya N; Sood I; Gupta SJ; Handa R
    Int J Rheum Dis; 2019 Sep; 22(9):1638-1643. PubMed ID: 31211501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity.
    Salaffi F; De Angelis R; Carotti M; Gutierrez M; Sarzi-Puttini P; Atzeni F
    Rheumatol Int; 2014 Aug; 34(8):1103-10. PubMed ID: 24509896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of ankylosing spondylitis disease activity score in evaluating disease activity of ankylosing spondylitis].
    DU XN; Li Y; Zhang SL; Zhu J; Huang F
    Zhonghua Nei Ke Za Zhi; 2012 Mar; 51(3):206-9. PubMed ID: 22781894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing Spondylitis Seen in Usual Clinical Care.
    Park SH; Choe JY; Kim SK; Lee H; Castrejón I; Pincus T
    J Clin Rheumatol; 2015 Sep; 21(6):300-4. PubMed ID: 26308349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
    Lukas C; Landewé R; Sieper J; Dougados M; Davis J; Braun J; van der Linden S; van der Heijde D;
    Ann Rheum Dis; 2009 Jan; 68(1):18-24. PubMed ID: 18625618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.